McKechnie Duncan's Form 4 filing
Vertex Pharmaceuticals IncVRTX · filed Feb 26, 2026
- Accession no.
- 0000875320-26-000116
- Filed
- Feb 26, 2026
- Trade date
- Feb 24-25, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions. Open-market sales total $2.39M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| McKechnie DuncanCIK 0002062139 | Officer (EVP, Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | Common Stock | FTax withholdingDisposed | −873 | $485.11 | −$423,501.03 | 22,469 | Direct | |
| Feb 25, 2026 | Common Stock | SSaleDisposed | −2,500 | $486.35 | −$1,215,875 | 19,969 | Direct | |
| Feb 25, 2026 | Common Stock | SSaleDisposed | −2,410 | $489.00 | −$1,178,490 | 17,559 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.